{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:19:33Z","timestamp":1778599173945,"version":"3.51.4"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2024-0189_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The study endeavored to evaluate the prolonged efficacy and safety of PEGylated rhGH (PEG-rhGH) administration in Chinese children diagnosed with growth hormone deficiency (GHD) over a 5-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2024-0189_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on children with GHD, who received a 0.2\u202fmg\/kg\/week dose of PEG-rhGH between 2016 and 2023 in our department.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2024-0189_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The height standard deviation score (Ht SDS) exhibited a marked elevation post-PEG-rhGH administration (p&lt;0.001), sustaining this enhancement beyond year 3, with increments recorded at 0.94\u00b10.37, 1.49\u00b10.48, 1.77\u00b10.51, 2.12\u00b10.65, and 2.15\u00b10.58 across 5 years. Similarly, the height velocity (HV), insulin-like growth factor-1 standard deviation score (IGF-1 SDS), and bone age to chronological age ratio (BA\/CA ratio) underwent significant augmentations (p&lt;0.01). Remarkably, no signs of rapid bone maturation were detected during the 5-year observation. Among the participants, 31 patients (59.62\u202f%) experienced adverse events, of which eight instances (15.38\u202f%) were classified as treatment-related adverse events, but none were severe or unexpected. Additionally, high-density lipoprotein (HDL) levels rose while low-density lipoprotein (LDL) levels fell, both remaining within the standard range throughout the treatment phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2024-0189_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administering PEG-rhGH at a dosage of 0.2\u202fmg\/kg\/week proved both effective and well-tolerated in treating prepubertal children with GHD. This regimen also demonstrated positive impacts on lipid metabolism over an extended treatment period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2024-0189","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:06:52Z","timestamp":1724346412000},"page":"892-899","source":"Crossref","is-referenced-by-count":4,"title":["Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study"],"prefix":"10.1515","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-4785","authenticated-orcid":false,"given":"Lele","family":"Hou","sequence":"first","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaofen","family":"Lin","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulin","family":"Liu","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ou","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Huang","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilian","family":"Dai","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Meng","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyang","family":"Liang","sequence":"additional","affiliation":[{"name":"Children\u2019s Medical Center , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"2026051215020579080_j_jpem-2024-0189_ref_001","doi-asserted-by":"crossref","unstructured":"Dehkhoda, F, Lee, CMM, Medina, J, Brooks, AJ. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. Front Endocrinol 2018;9:35. https:\/\/doi.org\/10.3389\/fendo.2018.00035.","DOI":"10.3389\/fendo.2018.00035"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_002","doi-asserted-by":"crossref","unstructured":"Wheeler, PG, Bresnahan, K, Shephard, BA, Lau, J, Balk, EM. Short stature and functional impairment: a systematic review. Arch Pediatr Adolesc Med 2004;158:236\u201343. https:\/\/doi.org\/10.1001\/archpedi.158.3.236.","DOI":"10.1001\/archpedi.158.3.236"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_003","doi-asserted-by":"crossref","unstructured":"Kao, KT, Stargatt, R, Zacharin, M. Adult quality of life and psychosocial outcomes of childhood onset hypopituitarism. Horm Res Paediatr 2015;84:94\u2013101. https:\/\/doi.org\/10.1159\/000430863.","DOI":"10.1159\/000430863"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_004","doi-asserted-by":"crossref","unstructured":"Chaplin, JE, Kristr\u00f6m, B, Jonsson, B, H\u00e4ggl\u00f6f, B, Tuvemo, T, Aronson, AS, et al.. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr 2011;75:291\u2013303. https:\/\/doi.org\/10.1159\/000322937.","DOI":"10.1159\/000322937"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_005","doi-asserted-by":"crossref","unstructured":"Grimberg, A, DiVall, SA, Polychronakos, C, Allen, DB, Cohen, LE, Quintos, JB, et al.. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361\u201397. https:\/\/doi.org\/10.1159\/000452150.","DOI":"10.1159\/000452150"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_006","doi-asserted-by":"crossref","unstructured":"Saenger, PH, Mejia-Corletto, J. Long-acting growth hormone: an update. Endocr Dev 2016;30:79\u201397. https:\/\/doi.org\/10.1159\/000439333.","DOI":"10.1159\/000439333"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_007","doi-asserted-by":"crossref","unstructured":"Christiansen, JS, Backeljauw, PF, Bidlingmaier, M, Biller, BM, Boguszewski, MC, Casanueva, FF, et al.. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol 2016;174:C1\u20138. https:\/\/doi.org\/10.1530\/eje-16-0111.","DOI":"10.1530\/EJE-16-0111"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_008","doi-asserted-by":"crossref","unstructured":"Webster, R, Xie, R, Didier, E, Finn, R, Finnessy, J, Edgington, A, et al.. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica 2008;38:1340\u201351. https:\/\/doi.org\/10.1080\/00498250802413856.","DOI":"10.1080\/00498250802413856"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_009","doi-asserted-by":"crossref","unstructured":"Rasmussen, MH, Bysted, BV, Anderson, TW, Klitgaard, T, Madsen, J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab 2010;95:3411\u20137. https:\/\/doi.org\/10.1210\/jc.2009-2813.","DOI":"10.1210\/jc.2009-2813"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_010","doi-asserted-by":"crossref","unstructured":"S\u00f8ndergaard, E, Klose, M, Hansen, M, Hansen, BS, Andersen, M, Feldt-Rasmussen, U, et al.. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 2011;96:681\u20138. https:\/\/doi.org\/10.1210\/jc.2010-1931.","DOI":"10.1210\/jc.2010-1931"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_011","doi-asserted-by":"crossref","unstructured":"Hou, L, Chen, ZH, Liu, D, Cheng, YG, Luo, XP. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Dev Ther 2015;10:13\u201321. https:\/\/doi.org\/10.2147\/dddt.s93183.","DOI":"10.2147\/DDDT.S93183"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_012","doi-asserted-by":"crossref","unstructured":"Luo, X, Hou, L, Liang, L, Dong, G, Shen, S, Zhao, Z, et al.. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol 2017;177:195\u2013205. https:\/\/doi.org\/10.1530\/eje-16-0905.","DOI":"10.1530\/EJE-16-0905"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_013","doi-asserted-by":"crossref","unstructured":"Luo, X, Zhao, S, Yang, Y, Dong, G, Chen, L, Li, P, et al.. Long-acting PEGylated growth hormone in children with idiopathic short stature. Eur J Endocrinol 2022;187:709\u201318. https:\/\/doi.org\/10.1530\/eje-22-0449.","DOI":"10.1530\/EJE-22-0449"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_014","doi-asserted-by":"crossref","unstructured":"Du, H, Wu, D, Yi, P, Bai, X, Luo, Y, Yang, H, et al.. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency. J Pediatr Endocrinol Metab 2022;35:511\u20137. https:\/\/doi.org\/10.1515\/jpem-2021-0735.","DOI":"10.1515\/jpem-2021-0735"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_015","doi-asserted-by":"crossref","unstructured":"Chen, J, Zhong, Y, Wei, H, Chen, S, Su, Z, Liu, L, et al.. Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study. BMC Endocr Disord 2022;22:201. https:\/\/doi.org\/10.1186\/s12902-022-01101-8.","DOI":"10.1186\/s12902-022-01101-8"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_016","doi-asserted-by":"crossref","unstructured":"Jiang, Z, Chen, X, Dong, G, Lou, Y, Zhang, J, Cheng, X, et al.. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: a randomized, dose-comparison study. Front Pharmacol 2022;13:955809. https:\/\/doi.org\/10.3389\/fphar.2022.955809.","DOI":"10.3389\/fphar.2022.955809"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_017","doi-asserted-by":"crossref","unstructured":"Sun, C, Lu, B, Liu, Y, Zhang, Y, Wei, H, Hu, X, et al.. Reduced effectiveness and comparable safety in biweekly vs. weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency: a phase IV non-inferiority threshold targeted trial. Front Endocrinol 2021;12:779365. https:\/\/doi.org\/10.3389\/fendo.2021.779365.","DOI":"10.3389\/fendo.2021.779365"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_018","doi-asserted-by":"crossref","unstructured":"Hou, L, Huang, K, Gong, C, Luo, F, Wei, H, Liang, L, et al.. Long-term pegylated GH for children with GH deficiency: a large, prospective, real-world study. J Clin Endocrinol Metab 2023;108:2078\u201386. https:\/\/doi.org\/10.1210\/clinem\/dgad039.","DOI":"10.1210\/clinem\/dgad039"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_019","unstructured":"Li, H, Ji, CY, Zong, XN, Zhang, YQ. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhong hua Er Ke Za Zhi 2009;47:487\u201392."},{"key":"2026051215020579080_j_jpem-2024-0189_ref_020","doi-asserted-by":"crossref","unstructured":"Cao, B, Peng, Y, Song, W, Peng, X, Hu, L, Liu, Z, et al.. Pediatric continuous reference intervals of serum insulin-like growth factor 1 levels in a healthy Chinese children population\u00a0\u2013 based on PRINCE study. Endocr Pract 2022;28:696\u2013702. https:\/\/doi.org\/10.1016\/j.eprac.2022.04.004.","DOI":"10.1016\/j.eprac.2022.04.004"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_021","doi-asserted-by":"crossref","unstructured":"Liang, Y, Zhang, C, Wei, H, Du, H, Zhang, G, Yang, Y, et al.. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency. Front Endocrinol 2022;13:922304. https:\/\/doi.org\/10.3389\/fendo.2022.922304.","DOI":"10.3389\/fendo.2022.922304"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_022","doi-asserted-by":"crossref","unstructured":"Cheng, R, Zhao, Q, Zhong, G, Xu, J, Zheng, Z, Xi, L, et al.. Population pharmacokinetic\/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals. Eur J Pharmaceut Sci 2022;179:106304. https:\/\/doi.org\/10.1016\/j.ejps.2022.106304.","DOI":"10.1016\/j.ejps.2022.106304"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_023","doi-asserted-by":"crossref","unstructured":"Pf\u00e4ffle, R. Hormone replacement therapy in children: the use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metabol 2015;29:339\u201352. https:\/\/doi.org\/10.1016\/j.beem.2015.04.009.","DOI":"10.1016\/j.beem.2015.04.009"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_024","doi-asserted-by":"crossref","unstructured":"Cohen, P, Rogol, AD, Howard, CP, Bright, GM, Kappelgaard, AM, Rosenfeld, RG, et al.. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480\u20136. https:\/\/doi.org\/10.1210\/jc.2007-0204.","DOI":"10.1210\/jc.2007-0204"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_025","doi-asserted-by":"crossref","unstructured":"Wang, C, Huang, H, Zhao, C, Zhao, J, Xiong, R, Jin, R, et al.. The impact of pegylated recombinant human growth hormone replacement therapy on glucose and lipid metabolism in children with growth hormone deficiency. Ann Palliat Med 2021;10:1809\u201314. https:\/\/doi.org\/10.21037\/apm-20-871.","DOI":"10.21037\/apm-20-871"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_026","doi-asserted-by":"crossref","unstructured":"Ciresi, A, Amato, MC, Criscimanna, A, Mattina, A, Vetro, C, Galluzzo, A, et al.. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 2007;156:353\u201360. https:\/\/doi.org\/10.1530\/eje.1.02343.","DOI":"10.1530\/eje.1.02343"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_027","doi-asserted-by":"crossref","unstructured":"Czepielewski, MA, Garret, Q, Vencio, SAC, Rassi, N, Felicio, JS, Faria, MS, et al.. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): a randomized, multicentric, investigator-blind, phase 3 trial. Growth Hormone IGF Res 2019;48-49:29\u201335. https:\/\/doi.org\/10.1016\/j.ghir.2019.07.003.","DOI":"10.1016\/j.ghir.2019.07.003"},{"key":"2026051215020579080_j_jpem-2024-0189_ref_028","doi-asserted-by":"crossref","unstructured":"Yuan, Y, Zhou, B, Liu, S, Wang, Y, Wang, K, Zhang, Z, et al.. Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy. Endocrine 2021;71:35\u201346. https:\/\/doi.org\/10.1007\/s12020-020-02435-w.","DOI":"10.1007\/s12020-020-02435-w"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0189\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:07:01Z","timestamp":1778598421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2024-0189\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,23]]},"published-print":{"date-parts":[[2024,10,28]]}},"alternative-id":["10.1515\/jpem-2024-0189"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0189","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}